GSTO1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Human hepatocellular carcinoma tissue, Hela cells, human fetal liver tissue, Primary antibody: P08387(GSTO1 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08387(GSTO1 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08387(GSTO1 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The glutathione S-transferase omega 1 (GSTO1) antibody is a tool used to detect and study the GSTO1 protein, a member of the glutathione S-transferase (GST) superfamily. GSTO1 is distinct from other GST classes due to its unique structural features and enzymatic activities, including deglutathionylation and thioltransferase functions. It localizes primarily in the cytoplasm and mitochondria, playing roles in oxidative stress response, detoxification, and regulation of apoptosis by modulating redox-sensitive signaling pathways. GSTO1 also interacts with interleukin-1β (IL-1β) precursors, influencing inflammatory processes.

Research highlights GSTO1's involvement in diseases such as neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s), cancer, and cardiovascular conditions. Polymorphisms in the GSTO1 gene are linked to altered susceptibility to these diseases. The GSTO1 antibody is crucial for applications like Western blotting, immunohistochemistry, and immunofluorescence to analyze protein expression, localization, and disease-associated changes. Validated antibodies help elucidate GSTO1's role in cellular redox homeostasis, drug metabolism, and pathological mechanisms. Both monoclonal and polyclonal variants are available, with specificity often confirmed via knockout controls. Its utility spans basic research, biomarker discovery, and therapeutic target validation.